HORMONE RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a popular weight loss drug help fight breast cancer?
Disease control Recruiting nowThis study is testing if the weight loss medication tirzepatide can help people with early-stage, hormone-positive breast cancer lose weight and potentially improve their long-term outcomes. It will involve 40 participants who have finished their main cancer treatment but are ove…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Apr 01, 2026 20:26 UTC
-
New drug combo aims to stop breast Cancer's comeback
Disease control Recruiting nowThis study is testing whether adding the drug ribociclib to standard hormone therapy can better prevent breast cancer from returning in patients who have already had a local recurrence surgically removed. The trial will enroll 200 adults with hormone-sensitive, HER2-negative brea…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Oana Danciu • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo aims to stop early breast cancer from coming back
Disease control Recruiting nowThis study is testing whether a combination of two targeted drugs (pertuzumab and trastuzumab) plus hormone therapy, given after surgery, can help prevent cancer from returning in people with early-stage, hormone-positive, HER2-positive breast cancer. About 375 participants will …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Triple-Threat treatment trial for spreading breast cancer
Disease control Recruiting nowThis study is testing whether combining three existing cancer drugs works better to control advanced breast cancer that has spread. It's for people whose cancer is fueled by hormones and has either just been diagnosed as advanced or returned after more than a year. The main goal …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
First human trial launches for promising new cancer pill targeting multiple tumors
Disease control Recruiting nowThis is an early-stage study testing a new oral drug called BG-68501 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for advanced breast cancer: experimental drug trial now recruiting
Disease control Recruiting nowThis early-stage study is testing a new experimental drug called BGB-43395, both alone and in combination with other cancer medications, for people with advanced hormone-positive breast cancer and other solid tumors. The main goals are to find safe dosage levels and see if the dr…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for breast cancer patients after first treatment fails
Disease control Recruiting nowThis study is testing whether the drug sacituzumab govitecan can help control metastatic breast cancer in people who have already received another targeted treatment called trastuzumab deruxtecan. The trial will enroll 75 adults with hormone receptor-positive, HER2-low breast can…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Reshma L. Mahtani, D.O. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New combo attack on spreading breast cancer
Disease control Recruiting nowThis early-stage study aims to find the safest and most effective dose of the drug abemaciclib when given at the same time as targeted radiation therapy. It is for people with advanced, hormone-sensitive breast cancer that has spread to the bones. The goal is to see if this combi…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for advanced breast cancer: testing Triple-Threat drug combo
Disease control Recruiting nowThis early-stage study is testing whether new drug combinations are safe for people with advanced hormone-positive breast cancer that has spread. Researchers will give 120 participants either two or three drugs together to see how well they're tolerated and if they help shrink tu…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Blood test could spare breast cancer patients from harsh chemo
Disease control Recruiting nowThis study is testing a personalized approach to reduce chemotherapy for women with a common type of early-stage breast cancer. It uses a simple blood test to see if a targeted pill (dalpiciclib) combined with hormone therapy works as well as standard chemo before surgery. The go…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New hope for Tough-to-Treat breast cancer: experimental combo enters human trials
Disease control Recruiting nowThis study is testing the safety and effectiveness of a new drug, VS-6766, when combined with two existing breast cancer drugs (abemaciclib and fulvestrant). It is for people with advanced HR+/HER2- breast cancer that has worsened despite prior standard treatments. The goal is to…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Breakthrough study tests four drug combos for male breast cancer
Disease control Recruiting nowThis study is testing which of four different hormone therapy combinations works best for men with early-stage breast cancer before surgery. About 60 men will receive one of the treatment combinations for about 4 months to see how their cancer responds. Researchers want to find b…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jose Pablo Leone • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for Tough-to-Treat breast cancer: two drugs vs. one
Disease control Recruiting nowThis study is testing if combining two drugs, capecitabine and elacestrant, works better than just capecitabine alone for people with advanced, hormone-sensitive breast cancer. It's for patients whose cancer has stopped responding to a common class of prior medications. The main …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug trial targets Tough-to-Treat breast cancer
Disease control Recruiting nowThis study is testing a new drug called EP0062, both alone and combined with standard treatments, for women with a specific type of advanced breast cancer that has come back after prior therapy. The main goals are to find the safest and most effective dose and to see how well the…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Scientists test 'Switchable' cell therapy to fight advanced breast cancer
Disease control Recruiting nowThis is an early study to test the safety of a new two-part treatment for people with advanced breast cancer that has spread or cannot be removed by surgery. The treatment involves giving patients their own modified immune cells (CLBR001), followed by a biologic drug (ABBV-461) t…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
New hope for advanced cancer patients as experimental drug trial begins
Disease control Recruiting nowThis is the first study in people to test a new drug called XB010 for advanced solid tumors. The main goals are to find a safe dose and see how the body handles the drug, both by itself and when combined with another cancer therapy. It is for adults with certain advanced cancers …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Feb 23, 2026 14:51 UTC
-
New hope for breast cancer patients suffering treatment side effects
Symptom relief Recruiting nowThis study is testing whether a vaginal suppository called Revaree Plus can improve vaginal health for women experiencing dryness and discomfort during breast cancer treatment. Researchers will enroll 60 women with hormone-receptor positive breast cancer who have completed primar…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Mar 27, 2026 12:41 UTC
-
Silent scans: hunting hidden brain cancer in breast patients
Knowledge-focused Recruiting nowThis study aims to find out if regular brain MRI scans can detect cancer that has spread to the brain in patients with advanced breast cancer who have no neurological symptoms. Researchers will enroll 170 patients with stage IV breast cancer to see how often these scans find hidd…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Blood test could tell doctors if breast cancer treatment will fail
Knowledge-focused Recruiting nowThis study is testing a blood test called DiviTum®TKa to see if it can predict early whether standard hormone-based treatments for advanced breast cancer will stop working. Researchers will measure a specific marker in the blood of 100 patients with hormone-positive, HER2-negativ…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC